EZH2 in B cell subsets.
The study by Rohraff et al. (1) points to the value of targeting EZH2 using the inhibitor DZNep in SLE with effects in prevention and treatment in a preclinical model. The modulation of epigenetic changes is of interest. Interestingly, our findings on the expression of EZH2 by B lineage cells are not consistent with this report with EZH2 being significantly upregulated in monocytes, neutrophils and CD19+ B cells of lupus patients. Here, EZH2 is almost exclusively increased in plasmablasts but not in memory and naïve B cells.